Aurinia Announces Appointment of Head of Communications & Advocacy VICTORIA, British Columbia--(BUSINESS WIRE)

Announces Appointment of Head of Communications & Advocacy

VICTORIA, British Columbia--(BUSINESS WIRE)--July 11, 2016--Aurinia

Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the

"Company"), a clinical stage pharmaceutical company focused on the

global nephrology market, today announced that it has appointed Celia

Economides to the newly created position of Associate Vice President,

Corporate Communications & Patient Advocacy.

Ms. Economides will lead the company's corporate communications, patient

advocacy and investor relations efforts.

Ms. Economides has over 15 years of experience in the life sciences and

biotech industries, spanning communications, finance, patient advocacy,

marketing and clinical development. She most recently served as a

Director in Global Medical Affairs at BioMarin Pharmaceutical, Inc.,

where she led both patient advocacy and competitive intelligence efforts

focusing on Duchenne Muscular Dystrophy. Previously, she led IR &

Corporate Communications at Prosensa, which was acquired by BioMarin in

January 2015. Prior to joining Prosensa, Ms. Economides was Director of

IR & Program Development at the Biotechnology Innovation Organization

(BIO), where she was responsible for BIO's outreach to the investment

community and working with emerging companies to improve their

communications and partnering activities. She led the program

development at BIO's annual investor and BD conferences and provided

industry research used in BIO's policy and advocacy activities. Prior to

BIO, Ms. Economides worked at a healthcare focused hedge fund and in

financial services focusing on the biotech sector. She began her career

working in research at Columbia University. She holds a Bachelor of Arts

(BA) degree from McGill University and a Master's in Public Health (MPH)

from Columbia University.

"We welcome Celia as an instrumental addition to our team," said Charles

Rowland, Aurinia's CEO. "Celia's depth and breadth of experience in the

biotech industry will support the company significantly as we continue

our efforts to advance voclosporin and deliver it to patients globally

while building value for our shareholders."

"I am pleased to join Aurinia at such a significant moment for the

company and look forward to working alongside a world-class team with

exceptional leadership in bringing treatments to patients in need," said

Celia Economides. "It is an honor to be able to share my experience and

contribute to the future direction and growth of a company working so

diligently to help patients suffering from serious and potentially

life-threatening conditions."

Aurinia is a clinical stage pharmaceutical company focused on the global

nephrology market. The fully-enrolled Phase 2b AURA-LV clinical trial is

evaluating the efficacy of its lead drug, voclosporin, as a treatment

for active LN. LN is an inflammation of the kidneys, that if

inadequately treated can lead to end-stage renal disease, making LN a

serious and potentially life-threatening condition.

We seek Safe Harbor.

Aurinia Pharmaceuticals Inc.

Michael Martin, 250-708-4272

Financial Communications Inc.

Barry Mire: bmire@renmarkfinancial.com

Welsh: lwelsh@renmarkfinancial.com

Tel: 416-644-2020 or